



# Highly Rifampin-Resistant *Listeria monocytogenes* Isolated from a Patient with Prosthetic Bone Infection

Viviane Chenal-Francisque, Caroline Charlier, Saleem Mehvish, H  l  ne Dieye,  
Alexandre Leclercq, Patrice Courvalin, Marc Lecuit

► To cite this version:

Viviane Chenal-Francisque, Caroline Charlier, Saleem Mehvish, H  l  ne Dieye, Alexandre Leclercq, et al.. Highly Rifampin-Resistant *Listeria monocytogenes* Isolated from a Patient with Prosthetic Bone Infection. Antimicrobial Agents and Chemotherapy, 2014, 58 (3), pp.1829-1830. 10.1128/AAC.02449-13 . pasteur-02870069

HAL Id: pasteur-02870069

<https://pasteur.hal.science/pasteur-02870069>

Submitted on 16 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Highly rifampicin-resistant *Listeria monocytogenes*  
 isolated from a patient with prosthetic bone infection**

Viviane Chenal-Francisque<sup>1,2</sup>, Caroline Charlier<sup>1,2,3,4</sup>, Saleem Mehvish<sup>4</sup>, Hélène Dieye<sup>1,2</sup>,  
 Alexandre Leclercq<sup>1,2</sup>, Patrice Courvalin<sup>5</sup>, Marc Lecuit<sup>1,2,3,4,\*</sup>

<sup>1</sup> Institut Pasteur, French National Reference Center and WHO collaborating Center for  
*Listeria*, Paris-F

<sup>2</sup> Institut Pasteur, Biology of Infection Unit, Paris-F

<sup>3</sup> Inserm U1117, Paris-F

<sup>4</sup> Paris Descartes University, Sorbonne Paris Cité, Division of Infectious Diseases and  
 Tropical Medicine, Necker-Enfants Malades University Hospital, Institut Imagine, Paris-F

<sup>5</sup> Institut Pasteur, Unité des Agents Antibactériens, Paris-France

\* Correspondence: marc.lecuit@pasteur.fr

16           Listeriosis is a rare but severe foodborne infection due to *Listeria monocytogenes* (*Lm*).  
17 *Lm* is naturally susceptible to a wide range of antibiotics, including penicillins,  
18 aminoglycosides, tetracyclines, macrolides, co-trimoxazole, linezolid, moxifloxacin,  
19 glycopeptides and rifampicin but not to cephalosporins (1-3). *Lm* resistance to antimicrobials  
20 is rare; it was estimated around 1.3% from 4,668 clinical isolates tested in the National  
21 Reference Centre for *Listeria* (NRCL) (3), involving mostly fluoroquinolones, but not  
22 rifampicin (1, 3-5).

23           We report here the characterization of a *Lm* human clinical isolate (CLIP 2009/01237)  
24 highly resistant to rifampicin. A 68-year-old male had protracted intra-medullar femoral nail  
25 infection. His history included radiotherapy for femoral plasmocytoma with subsequent  
26 fractures. He presented with pain and instability, and was afebrile. A purulent collection was  
27 evidenced and the prosthetic device removed, albeit incompletely. Pus cultures remained  
28 sterile and he was discharged without treatment. He was readmitted four weeks later with  
29 fever and pus flow emitted from the operative site. As pneumonia was suspected, he received  
30 ceftriaxone and ciprofloxacin for 48 hours. A collection in the femoral region formed, and  
31 surgical debridement was performed. Pus grew *Lm*. As for most sporadic cases of listeriosis,  
32 the contamination source was not identified. Amoxicillin 6g/d was prescribed.

33           *Lm* identification was confirmed using the API *Listeria* system (bioMérieux, Marcy  
34 l'Etoile, France) and the strain typed as belonging to genosero-group IVb (6). Susceptibility to  
35 antibiotics was determined by disk diffusion according to the European Committee on  
36 Antimicrobial Susceptibility Testing (EUCAST) guidelines (3, 7-8). The strain was resistant  
37 to high-levels of rifampicin but otherwise susceptible. The MIC of rifampicin was > 32 µg/ml,  
38 as determined by Etest (bioMérieux).

39           Resistance to rifampicin is mostly mediated by mutations in *rpoB*, which encodes the  
40 β-subunit of the RNA polymerase, and mutations in *rpoB* have been associated with

41 resistance to rifampicin (9-11). The *rpoB* gene (3,555 bp) of this rifampicin-resistant isolate  
42 was amplified and sequenced. Comparisons with *rpoB* of susceptible strain (12) identified  
43 missense mutation S488L in a conserved domain previously shown to be associated with  
44 rifampicin resistance (“resistance locus”) in both *E. coli* and *Lm* mutants obtained *in vitro*  
45 (13). A similar substitution (S531L) has been reported in the central region of the  $\beta$ -subunit of  
46 the RNA polymerase of rifampicin-resistant *M. tuberculosis* (11). Another non-synonymous  
47 mutation was detected at codon 1178 (A1178T).

48       To our knowledge, S488L and A1178T substitutions have not been described in *Lm*  
49 (14). This strain was the only one displaying high resistance to rifampicin among the 5,114  
50 human isolates tested in the NRCL since 1994. A single isolate from another patient with a  
51 borderline rifampicin MIC (4 $\mu$ g/ml) did not exhibit any mutation in the *rpoB* resistance locus  
52 (our unpublished data).

53       According to the information we have, this patient was not exposed to rifampicin,  
54 arguing for a mechanism reminiscent to spontaneously arising *M. tuberculosis* resistance to  
55 rifampicin in infections with large inoculum (11). Mutations in *rpoB* reported here could also  
56 be the consequence of the previous ciprofloxacin-exposure, which has been shown to promote  
57 mutations associated with rifampicin-resistance in *Staphylococcus aureus* (15). To our  
58 knowledge, we provide here the first report of a highly rifampicin-resistant *Lm* human clinical  
59 isolate.

60

61 **References**

- 62
- 63 1. **Charpentier E, Courvalin P.** 1999. Antibiotic resistance in *Listeria* spp. *Antimicrob*
- 64 *Agents Chemother* **43**:2103-2108.
- 65 2. **Hof H, Nichterlein T, Kretschmar M.** 1997. Management of listeriosis. *Clin*
- 66 *Microbiol Rev* **10**:345-357.
- 67 3. **Morvan A, Moubareck C, Leclercq A, Herve-Bazin M, Bremont S, Lecuit M,**
- 68 **Courvalin P, Le Monnier A.** 2010. Antimicrobial resistance of *Listeria*
- 69 *monocytogenes* strains isolated from humans in France. *Antimicrob Agents*
- 70 *Chemother* **54**:2728-2731.
- 71 4. **Granier SA, Moubareck C, Colaneri C, Lemire A, Roussel S, Dao TT, Courvalin**
- 72 **P, Brisabois A.** Antimicrobial resistance of *Listeria monocytogenes* isolates from
- 73 food and the environment in France over a 10-year period. *Appl Environ Microbiol*
- 74 **77**:2788-2790.
- 75 5. **(EUCAST) ECoAST** 2013, posting date. European Committee on Antimicrobial
- 76 *Susceptibility Testing (EUCAST)* 2013. Breakpoint tables for interpretation of MICs
- 77 and zone diameters. Table v. 3.1. [http://www.eucast.org/clinical\\_breakpoints/](http://www.eucast.org/clinical_breakpoints/). *Listeria*
- 78 *monocytogenes*, page 68. . [Online.]
- 79 6. **Doumith M, Buchrieser C, Glaser P, Jacquet C, Martin P.** 2004. Differentiation of
- 80 the major *Listeria monocytogenes* serovars by multiplex PCR. *J Clin Microbiol*
- 81 **42**:3819-3822.
- 82 7. **(CLSI) CaLSI.** 2010. Methods for antimicrobial dilution and disk susceptibility
- 83 testing of infrequently isolated or fastidious bacteria; Approved Guideline-Second
- 84 Edition (Document M45-A2). Clinical and Laboratory Standards Institute, Wayne, PA.
- 85 8. **(CLSI) CaLSI.** 2012. Performance standards for antimicrobial disk susceptibility
- 86 tests; Approved standard – Eleventh edition (Document M2-A9), Clinical and
- 87 Laboratory Standards Institute, Wayne, PA.
- 88 9. **Aubry-Damon H, Galimand M, Gerbaud G, Courvalin P.** 2002. *rpoB* mutation
- 89 conferring rifampin resistance in *Streptococcus pyogenes*. *Antimicrob Agents*
- 90 *Chemother* **46**:1571-1573.
- 91 10. **Aubry-Damon H, Soussy CJ, Courvalin P.** 1998. Characterization of mutations in
- 92 the *rpoB* gene that confer rifampin resistance in *Staphylococcus aureus*. *Antimicrob*
- 93 *Agents Chemother* **42**:2590-2594.
- 94 11. **Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Matter L,**
- 95 **Schopfer K, Bodmer T.** 1993. Detection of rifampicin-resistance mutations in
- 96 *Mycobacterium tuberculosis*. *Lancet* **341**:647-650.
- 97 12. **Nelson KE, Fouts DE, Mongodin EF, Ravel J, DeBoy RT, Kolonay JF, Rasko DA,**
- 98 **Angiuoli SV, Gill SR, Paulsen IT, Peterson J, White O, Nelson WC, Nierman W,**
- 99 **Beanan MJ, Brinkac LM, Daugherty SC, Dodson RJ, Durkin AS, Madupu R,**
- 100 **Haft DH, Selengut J, Van Aken S, Khouri H, Fedorova N, Forberger H, Tran B,**
- 101 **Kathariou S, Wonderling LD, Uhlich GA, Bayles DO, Luchansky JB, Fraser CM.**
- 102 2004. Whole genome comparisons of serotype 4b and 1/2a strains of the food-borne
- 103 pathogen *Listeria monocytogenes* reveal new insights into the core genome
- 104 components of this species. *Nucleic Acids Res* **32**:2386-2395.
- 105 13. **Gariyban L, Huang T, Kim M, Wolff E, Nguyen A, Nguyen T, Diep A, Hu K,**
- 106 **Iverson A, Yang H, Miller JH.** 2003. Use of the *rpoB* gene to determine the
- 107 specificity of base substitution mutations on the *Escherichia coli* chromosome. *DNA*
- 108 *Repair (Amst)* **2**:593-608.

- 109 14. **Morse R, O'Hanlon K, Virji M, Collins MD.** 1999. Isolation of rifampin-resistant  
110 mutants of *Listeria monocytogenes* and their characterization by *rpoB* gene  
111 sequencing, temperature sensitivity for growth, and interaction with an epithelial cell  
112 line. *J Clin Microbiol* **37**:2913-2919.
- 113 15. **Didier JP, Villet R, Huggler E, Lew DP, Hooper DC, Kelley WL, Vaudaux P.**  
114 2011. Impact of ciprofloxacin exposure on *Staphylococcus aureus* genomic alterations  
115 linked with emergence of rifampin resistance. *Antimicrob Agents Chemother*  
116 **55**:1946-1952.  
117  
118